Bausch & Lomb IPO to be one of 2013's largest
This article was originally published in Scrip
Bausch & Lomb entertained acquisition offers, but has decided to pursue an initial public offering instead - a strategy in line with CEO Brent Saunders' assertion in January that the ophthalmology company likely would return to the public markets.
You may also be interested in...
Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.
CAR-T therapy-associated T-cell malignancies that the US FDA is investigating could make the treatments less attractive in autoimmune diseases than in oncology, but patients in both settings already accept some cancer risk with other available medicines.
SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply.